A Randomized, Double-blind, Placebo-controlled, Multicenter, Entecavir-based, Phase III Clinical Trial of Hydronidone Capsule in the Treatment of Liver Fibrosis Associated with Chronic Hepatitis B
Latest Information Update: 28 May 2025
At a glance
- Drugs Hydronidone (Primary)
- Indications Hepatic fibrosis
- Focus Registrational; Therapeutic Use
- Sponsors Beijing Continent Pharmaceutical
Most Recent Events
- 22 May 2025 According to Gyre Therapeutics media release,Based on positive results from this study the company plans to file an NDA with Chinas NMPA in the third quarter of 2025.
- 22 May 2025 Primary endpoint (Change in Ishak stage score of liver fibrosis by greater than or equal to 1 point after 52 weeks of treatment relative to baseline.) has been met.
- 22 May 2025 Results presented in the Gyre Therapeutics Media Release.